Merck and Moderna said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced skin cancer recurrence and spread compared with Keytruda alone, the first positive late-stage trial results for an mRNA cancer vaccine. Shares...
Continue reading...
[ H/T Newsmax ]
